APS ACTION--AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking
D Erkan, M D Lockshin, APS ACTION members, Laura Andreoli, Ware Branch, Robin Brey, Ricard Cervera, Hannah Cohen, Maria Cuadrado, Philip deGroot, Ronald Derksen, Doruk Erkan, Paul Fortin, Bill Giannakopoulos, Nigel Harris, Munther Khamashta, Steve Krilis, Steven R Levine, Roger Levy, Michael Lockshin, Sam Machin, Pierluigi Meroni, Tom Ortel, Vittorio Pengo, Silvia Pierangeli, Guillermo Pons-Estel, Jacob Rand, Robert Roubey, Jane Salmon, Angela Tincani, Denis Wahl, Alessandra Banzato, Cecilia B Chighizola, Guilherme de Jesus, D Erkan, M D Lockshin, APS ACTION members, Laura Andreoli, Ware Branch, Robin Brey, Ricard Cervera, Hannah Cohen, Maria Cuadrado, Philip deGroot, Ronald Derksen, Doruk Erkan, Paul Fortin, Bill Giannakopoulos, Nigel Harris, Munther Khamashta, Steve Krilis, Steven R Levine, Roger Levy, Michael Lockshin, Sam Machin, Pierluigi Meroni, Tom Ortel, Vittorio Pengo, Silvia Pierangeli, Guillermo Pons-Estel, Jacob Rand, Robert Roubey, Jane Salmon, Angela Tincani, Denis Wahl, Alessandra Banzato, Cecilia B Chighizola, Guilherme de Jesus
Abstract
AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is the first-ever international research network that has been created specifically to design and conduct well-designed, large-scale, multi-center clinical trials in persistently antiphospholipid antibody (aPL)-positive patients. The founding principle of the APS ACTION is that it is an internationally collaborative effort, open to qualified investigators across the globe who are committed to furthering our understanding of APS and its management. Due to the hard work and collaborative spirit of APS ACTION members, in early 2012, APS ACTION launched two important collaborative international projects: 1) a randomized controlled trial of hydroxychloroquine in the primary thrombosis prevention of persistently aPL-positive but thrombosis-free patients without other systemic autoimmune diseases; and 2) a web-based registry of aPL-positive patients with or without systemic autoimmune diseases, which will also include annual blood collection for aPL-testing and future basic science studies. In the end, we hope to find better treatments for antiphospholipid syndrome, which is a leading cause of thrombosis, pregnancy morbidity and other life-altering consequences, and to heighten awareness about this life-threatening, autoimmune condition.
Figures
Source: PubMed